UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000021960
Receipt No. R000025318
Scientific Title Circulating Serpina3 / EGFR levels in type 2 diabetes patients before and after administering the GLP-1 receptor agonists.
Date of disclosure of the study information 2016/04/19
Last modified on 2016/04/18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Circulating Serpina3 / EGFR levels in type 2 diabetes patients before and after administering the GLP-1 receptor agonists.
Acronym Circulating Serpina3 / EGFR levels in type 2 diabetes patients before and after administering the GLP-1 receptor agonists.
Scientific Title Circulating Serpina3 / EGFR levels in type 2 diabetes patients before and after administering the GLP-1 receptor agonists.
Scientific Title:Acronym Circulating Serpina3 / EGFR levels in type 2 diabetes patients before and after administering the GLP-1 receptor agonists.
Region
Japan

Condition
Condition Type 2 diabetes
Classification by specialty
Medicine in general Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the physiological significance of serum Serpina3 and EGFR in patients with type 2 diabetes before and after administering GLP-1 receptor agonist.
Basic objectives2 Others
Basic objectives -Others To determine the physiological significance.
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes The changes in serum Serpina3 / EGFR levels in type 2 diabetes patients before and after administering the GLP-1 receptor agonists.
Key secondary outcomes The association of metabolic parameters with the difference in serum Serpina3 / EGFR levels in type 2 diabetes patients between before and after administering GLP-1 receptor agonist.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Outpatients and inpatients with type 2 diabetes who fulfilled the following criteria.
<GLP-1 receptor agonists group>
1) Age is over 20.
2) Patients diagnosed with type 2 diabetes.
3) Patients scheduled to start the treatment with GLP-1 receptor agonist.
4) Having provided voluntary written consent for participation in this study.
<Control group (insulin group)>
1) Age is over 20.
2) Patients diagnosed with type 2 diabetes.
3) Patients scheduled to start the treatment with insulin injection.
4) Having provided voluntary written consent for participation in this study.
Key exclusion criteria Patients corresponding to any of the following are inapplicable in the both GLP-1 receptor agonists group and control group.
1)Patients who ingest the DPP-4 inhibitors.
2)Patients with severe complications (liver disease, mental disorder, or cancer).
3)Patients with severe ketosis or diabetic coma.
4)Patients with severe infections, perioperative status, or severe trauma.
5)Patients whose baseline eGFR were <29 ml/min/1.73m^2.
6)Pregnancy or lactation in women.
7)Patients who are judged by an investigator to be inappropriate for this study for any other reason.
Target sample size 20

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yasuo Terauchi
Organization Yokohama City University Graduate School of Medicine
Division name Department of Endocrinology and Metabolism
Zip code
Address 3-9 Fukuura, Kanazawa-ku, Yokohama
TEL 045-787-2800
Email terauchi@yokohama-cu.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Mayu Kyohara
Organization Yokohama City University Graduate School of Medicine
Division name Department of Endocrinology and Metabolism
Zip code
Address 3-9 Fukuura, Kanazawa-ku, Yokohama
TEL 045-787-2800
Homepage URL
Email kyouhara-tym@umin.ac.jp

Sponsor
Institute Yokohama City University hospital
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 04 Month 19 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2016 Year 03 Month 10 Day
Date of IRB
Anticipated trial start date
2016 Year 04 Month 19 Day
Last follow-up date
2018 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Cross-sectional study
Recruitment of Subject:
Outpatients and inpatients with type 2 diabetes in Yokohama City University hospital who fulfilled the inclusion/exclusion criteria.
To evaluate the physiological significance of serum Serpina3 and EGFR in patients with type 2 diabetes before and after administering GLP-1 receptor agonist.

Management information
Registered date
2016 Year 04 Month 18 Day
Last modified on
2016 Year 04 Month 18 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025318

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.